Type 2 Diabetes

In this special edition episode, hosts break down what the announcement of the 10 drugs selected for Medicare price negotiations under the Inflation Reduction Act means for providers and people with diabetes.

Citing more than half a dozen major trials in the 2 years since the release of their 2021 heart failure guidelines, the European Society of Cardiology has released a focused update to their heart failure guidance.

An analysis of data from more than 30,000 people with type 2 diabetes provides insight into the long-term use of metformin and risk of vitamin B12 deficiency.

An analysis of data from CREDENCE provides insight into the prognostic potential of a group of 4 common biomarkers for predicting cardiovascular and kidney issues in people with type 2 diabetes.

In this episode, Isaacs and Bellini sit down with Dawn Noe, RDN, LD, for a discussion surrounding her journey into diabetes care, the importance of individualizing nutrition in diabetes management, and the sessions she led and moderated at ADCES 2023.

Using data and eligibility criteria from the STEP 1 trial, a California-based team estimates 93 million US adults met criteria for semaglutide 2.4 mg and use could prevent 1.5 million incident cardiovascular events over a 10-year period.

In this episode, which is the first of multiple special edition ADCES 2023 episodes, hosts hold an overarching discussion of the meeting itself and major themes from the ADCES's 50th anniversary celebration.

In this episode, hosts take time to break down the implications of two, potentially paradigm-shifting news in the announcement of the addition of bexagliflozin to the Cost Plus Drugs platform and topline data from the landmark SELECT trial.

In a Q&A, Clipper Young, PharmD, MPH, discusses the Pharm2Home Initiative based on his presentation from ADCES 2023 and describes the impact of community-driven, pharmacist-led interventions to improve health literacy in those with chronic disease.

Joshua Neumiller, PharmD, takes part in a Q&A on the role of deprescribing in older adults with diabetes mellitus based on a presentation from the Association of Diabetes Care and Education Specialists 2023 annual meeting.

This endocrine case report feature a woman with a history of diabetes, hypertension, and marijuana use in her mid 50s brought to the ED for confusion by her friend and neighbor who states that she has been like this for 3 days. Can you determine how best to proceed?

Our July 2023 endocrinology month in review features an FDA approval, topline results from a pair of major trials, and a pair of new guidelines related to the management and diagnosis of diabetes.

On July 27, 2023, Eli Lilly and Company announced topline results of the SURMOUNT-3 and SURMOUNT-4 trials, with both trials achieving all primary endpoints of interest and full results scheduled to be presented later this year.

A meta-analysis of 20 studies suggests a vegetarian diet was associated with significant reductions in LDL-C, HbA1c, and body weight in individuals at high risk of CVDs.

The American Diabetes Association, together with the American Association of Clinical Chemistry, has released a new, 49-page document outlining optimized guidance for use of laboratory analysis in the diagnosis and management of diabetes.

However, the analysis suggests young adults with T2D who underwent vitrectomy for PDR had worse final visual acuity and more complications compared to those with T1D.

An analysis of EHR data recorded from 2018-2022 within Duke University Medical Center-affiliated diabetes care centers suggests the increased rate of new-onset type 1 and type 2 diabetes observed during the first year of the pandemic persisted through 2022.

Real-world evidence suggests the rapid reduction of HbA1c is not associated with early worsening in subjects with T2D with mild or moderate nonproliferative DR.

With the popularity of the class skyrocketing, the American Society of Anesthesiologists has released new guidance urging patients to withhold GLP-1 receptor agonist use prior to elective surgeries or procedures based on potential risk of regurgitation and aspiration associated with delayed gastric emptying.

A microsimulation model leveraging data from NHANES suggests monthly prescriptions of fruits and vegetables to people with diabetes and food insecurity could prevent nearly 300,000 cardiovascular disease events over a 25-year period.

Crisis Point returns with an episode on cardiometabolic health disparities, as 3 experts unravel the scope of the crisis, from its historical basis to ongoing social determinants of health in the modern age.

After a whirlwind conference packed with special episodes and late-breaking data, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, sit down to discuss their top takeaways from ADA 2023.

Announced by Tandem Diabetes Care on July 11, 2023, the Tandem Mobi insulin pump is billed as the world's smallest insulin pump, at less than half the size of the t:slim X2 pump and able to fit in a coin pocket.

Hosts are joined by Gary Scheiner, MS, of Integrated Diabetes Services, to discuss the latest developments in diabetes technology from the floor of the 83rd Scientific Sessions of the American Diabetes Association.

Expansions in access by the Centers of Medicare and Medicaid Services could bring the latest advances in continuous glucose monitoring into the hands of millions with diabetes, which could provide significant, population-level impact and bring the field a step closer to equitable diabetes management.

Our endocrinology month in review for June 2023, highlights FDA decisions in type 1 and type 2 diabetes, studies from ENDO 2023, and new data presented at the 83rd Scientific Sessions of the American Diabetes Association.

David Ahn, MD, joins our hosts for a discussion on overcoming barriers with diabetes technology and offers perspective on his experience leveraging social media platforms to disseminate information as a clinician.

Julie Heverly, of the Time in Range Coalition, discusses the history of time in range, offers perspective on its utility as a glucose metric, and provides an overview of the efforts of the Time in Range Coalition to advance use and education around time in range.

However, the presence of diabetic retinopathy was observed to have no significant impact on physical health and quality of life compared to subjects without retinopathy.

A recap of the top news from the 83rd Scientific Sessions of the American Diabetes Association, including data related to retatrutide, tirzepatide, oral semaglutide, and more!